WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407474
CAS#: 1259484-97-3
Description: SKI-178 is a sphingosine kinase 1 (SphK1) inhibitor (IC50 = 0.1-1.8 μM). SKI-178 induces prolonged mitosis followed by apoptotic cell death through the intrinsic apoptotic cascade. The sustained activation of CDK1 during prolonged mitosis, mediated by SKI-178 leads to the simultaneous phosphorylation of the prosurvival Bcl-2 family members, Bcl-2 and Bcl-xl, as well as the phosphorylation and subsequent degradation of Mcl-1. SKI-178 is a novel therapeutic agent for the treatment of AML, including multidrug-resistant/recurrent AML subtypes.
MedKoo Cat#: 407474
Name: SKI-178
CAS#: 1259484-97-3
Chemical Formula: C21H22N4O4
Exact Mass: 394.1641
Molecular Weight: 394.431
Elemental Analysis: C, 63.95; H, 5.62; N, 14.20; O, 16.22
Synonym: SKI-178; SKI 178; SKI178.
IUPAC/Chemical Name: N'-(1-(3,4-Dimethoxyphenyl)ethylidene)-3-(4-methoxyphenyl)-1H-pyrazole-5-carbohydrazide
InChi Key: GMFUWEBOUKIKRP-LPYMAVHISA-N
InChi Code: InChI=1S/C21H22N4O4/c1-13(15-7-10-19(28-3)20(11-15)29-4)22-25-21(26)18-12-17(23-24-18)14-5-8-16(27-2)9-6-14/h5-12H,1-4H3,(H,23,24)(H,25,26)/b22-13+
SMILES Code: O=C(C1=CC(C2=CC=C(OC)C=C2)=NN1)N/N=C(C3=CC=C(OC)C(OC)=C3)\C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 394.431 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: LeBlanc FR, Liu X, Hengst J, Fox T, Calvert V, Petricoin EF 3rd, Yun J, Feith
DJ, Loughran TP Jr. Sphingosine kinase inhibitors decrease viability and induce
cell death in natural killer-large granular lymphocyte leukemia. Cancer Biol
Ther. 2015;16(12):1830-40. doi: 10.1080/15384047.2015.1078949. PubMed PMID:
26252351; PubMed Central PMCID: PMC4847818.
2: Dick TE, Hengst JA, Fox TE, Colledge AL, Kale VP, Sung SS, Sharma A, Amin S,
Loughran TP Jr, Kester M, Wang HG, Yun JK. The apoptotic mechanism of action of
the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid
leukemia cell lines. J Pharmacol Exp Ther. 2015 Mar;352(3):494-508. doi:
10.1124/jpet.114.219659. Epub 2015 Jan 6. PubMed PMID: 25563902; PubMed Central
PMCID: PMC4352591.
3: Hengst JA, Wang X, Sk UH, Sharma AK, Amin S, Yun JK. Development of a
sphingosine kinase 1 specific small-molecule inhibitor. Bioorg Med Chem Lett.
2010 Dec 15;20(24):7498-502. doi: 10.1016/j.bmcl.2010.10.005. Epub 2010 Nov 1.
PubMed PMID: 21050755.
